Jubilant Ingrevia Achieves 12% YoY Revenue Growth in Q4'FY26; Strong Performance Driven by Specialty Chemicals

Jubilant Ingrevia Achieves 12% YoY Revenue Growth in Q4'FY26; Strong Performance Driven by Specialty Chemicals​

Jubilant Ingrevia Limited announced its financial results for the quarter and financial year ended March 31, 2026. The company reported a robust performance in Q4, with Total Revenue growing 12% Year-over-Year (YoY) and EBITDA increasing 11% YoY, driven by strong execution across its core segments.

Management highlighted that the company effectively handled the Middle East crisis throughout the quarter, reporting zero production loss and no force majeure events. Key operational achievements included successful dispatch from the newly constructed Agro CDMO facility and the acceleration of the Human Nutrition business following the acquisition of Remidex.

The Board of Directors also recommended a final dividend of ₹2.50 per share (250%), bringing the total Year-over-Year dividend for FY26 to ₹5 per share (500%).

Consolidated Financial Highlights​

The company posted impressive growth metrics in Q4'FY26 compared to the previous year. The financial performance figures for the quarter and full fiscal year are summarized below:


Furthermore, the Basic and Diluted Earnings Per Share (EPS) showed significant growth, rising to ₹5.5 in Q4'FY26, reflecting an 84% Quarter-over-Quarter and 17% Year-over-Year increase.

Segment Performance Deep Dive​

Performance was led by Specialty Chemicals and Nutrition & Health Solutions, which together contributed 85%+ of the overall EBITDA.

Specialty Chemicals​

The Specialty Chemicals segment remains a key growth pillar. For Q4'FY26, the segment revenue reached 516 crore, marking a 13% Quarter-over-Quarter (QoQ) increase and 6% Year-over-Year (YoY) growth. EBITDA for the segment stood at 139 crore, up 20% QoQ and 8% YoY.

For the full fiscal year, Specialty Chemicals revenue grew to 1,937 crore, up 7% YoY, with EBITDA reaching 510 crore, a 21% YoY increase. The segment maintains a strong EBITDA margin of 27% in Q4'FY26.

Business momentum was seen in multiple areas:

• P&P: Saw strong volume momentum in Pyridine & Picolines.
• CDMO: The segment benefited from the commencement of a big CDMO order for Agro, reflecting a shift toward value-added products.
• Semicon: Construction of an R&D lab at Greater Noida with a clean room signifies increasing capability in the semiconductor sector.

Nutrition & Health Solutions​

The Nutrition & Health Solutions segment demonstrated strong volume and pricing-led growth. Segment revenue for Q4'FY26 was 230 crore, up 15% QoQ and 21% YoY. EBITDA climbed to 32 crore, a 42% QoQ increase.

The segment's growth was largely driven by:

• Human Nutrition: Experienced steady YoY growth in food and cosmetic volumes.
• Animal Nutrition: Achieved the highest volumes in the past eight quarters, supported by improved pricing.
• Strategy: The completion of the Remidex Pharma acquisition strengthened the Human Nutrition Premixes portfolio.

Chemical Intermediates​

The Chemical Intermediates segment reported a revenue of 433 crore in Q4'FY26, showing a 10% QoQ rise and 15% YoY growth. The EBITDA improved significantly, standing at 22 crore (45% QoQ).

The segment's growth drivers included:

• Acetic Anhydride: Showed overall volume growth supported by resilient Pharma demand in India and increased market share in Europe.
• Ethyl Acetate: Experienced double-digit volume growth on both QoQ and YoY bases, supported by higher raw material costs amid Middle East disruptions.

Future Outlook and Growth Pillars​

The company highlighted that early outcomes of its "Pinnacle Journey" are contributing to the current performance, characterized by strong EBITDA growth and an improved portfolio mix.

For FY27, the company expects growth to be spearheaded by Specialty Chemicals and Nutrition, along with a recovery expected in Acetyls. Management is confident of sustained growth across segments due to improving volume demand and escalated pricing.

The company remains committed to capacity expansion, with the construction of the Gajraula Multi Purpose Plant (MPP) progressing well to strengthen the CDMO growth roadmap.

Key Strategic Milestones:

• The company successfully commissioned its CDMO plant at Bharuch in record 14 months.
• The acquisition of Remidex Pharma was completed to boost the Human Nutrition Premixes portfolio.
• The operational strategy involves a verticalized structure, focusing on Nutrition, Pharma, Agro, Cosmetics, Industrial, and Semicon segments.

JUBLINGREA Stock Price Movement​

Shares of Jubilant Ingrevia Limited slipped by 5.10% today, settling at ₹694.50 in post-market trading. The stock witnessed considerable activity during the session, trading a total volume of 839,118 shares.